|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: USO1 |
Gene summary for USO1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | USO1 | Gene ID | 8615 |
| Gene name | USO1 vesicle transport factor | |
| Gene Alias | P115 | |
| Cytomap | 4q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O60763 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8615 | USO1 | LZE4T | Human | Esophagus | ESCC | 1.93e-10 | 3.36e-01 | 0.0811 |
| 8615 | USO1 | LZE5T | Human | Esophagus | ESCC | 2.09e-04 | 3.36e-01 | 0.0514 |
| 8615 | USO1 | LZE7T | Human | Esophagus | ESCC | 1.27e-02 | 4.57e-01 | 0.0667 |
| 8615 | USO1 | LZE8T | Human | Esophagus | ESCC | 2.73e-09 | 3.13e-01 | 0.067 |
| 8615 | USO1 | LZE20T | Human | Esophagus | ESCC | 1.35e-07 | 1.68e-01 | 0.0662 |
| 8615 | USO1 | LZE21D1 | Human | Esophagus | HGIN | 5.04e-03 | 1.28e-01 | 0.0632 |
| 8615 | USO1 | LZE24T | Human | Esophagus | ESCC | 2.44e-10 | 3.15e-01 | 0.0596 |
| 8615 | USO1 | LZE21T | Human | Esophagus | ESCC | 3.30e-06 | 3.07e-01 | 0.0655 |
| 8615 | USO1 | P1T-E | Human | Esophagus | ESCC | 6.57e-09 | 7.64e-01 | 0.0875 |
| 8615 | USO1 | P2T-E | Human | Esophagus | ESCC | 5.95e-43 | 8.64e-01 | 0.1177 |
| 8615 | USO1 | P4T-E | Human | Esophagus | ESCC | 5.19e-28 | 7.63e-01 | 0.1323 |
| 8615 | USO1 | P5T-E | Human | Esophagus | ESCC | 3.54e-12 | 1.95e-01 | 0.1327 |
| 8615 | USO1 | P8T-E | Human | Esophagus | ESCC | 8.66e-26 | 2.58e-01 | 0.0889 |
| 8615 | USO1 | P9T-E | Human | Esophagus | ESCC | 1.94e-16 | 2.93e-01 | 0.1131 |
| 8615 | USO1 | P10T-E | Human | Esophagus | ESCC | 2.91e-23 | 4.31e-01 | 0.116 |
| 8615 | USO1 | P11T-E | Human | Esophagus | ESCC | 2.29e-10 | 8.23e-01 | 0.1426 |
| 8615 | USO1 | P12T-E | Human | Esophagus | ESCC | 1.07e-28 | 4.68e-01 | 0.1122 |
| 8615 | USO1 | P15T-E | Human | Esophagus | ESCC | 2.36e-16 | 4.23e-01 | 0.1149 |
| 8615 | USO1 | P16T-E | Human | Esophagus | ESCC | 2.23e-29 | 6.26e-01 | 0.1153 |
| 8615 | USO1 | P17T-E | Human | Esophagus | ESCC | 6.05e-10 | 5.57e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004819317 | Esophagus | HGIN | Golgi vesicle transport | 83/2587 | 296/18723 | 8.59e-11 | 8.89e-09 | 83 |
| GO:00068889 | Esophagus | HGIN | endoplasmic reticulum to Golgi vesicle-mediated transport | 40/2587 | 130/18723 | 4.67e-07 | 2.07e-05 | 40 |
| GO:00160509 | Esophagus | HGIN | vesicle organization | 65/2587 | 300/18723 | 1.24e-04 | 2.54e-03 | 65 |
| GO:004343420 | Esophagus | HGIN | response to peptide hormone | 79/2587 | 414/18723 | 1.60e-03 | 1.79e-02 | 79 |
| GO:190165318 | Esophagus | HGIN | cellular response to peptide | 68/2587 | 359/18723 | 3.88e-03 | 3.54e-02 | 68 |
| GO:005164810 | Esophagus | HGIN | vesicle localization | 37/2587 | 177/18723 | 6.03e-03 | 4.87e-02 | 37 |
| GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
| GO:001605014 | Esophagus | ESCC | vesicle organization | 211/8552 | 300/18723 | 2.85e-18 | 2.87e-16 | 211 |
| GO:000688815 | Esophagus | ESCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 102/8552 | 130/18723 | 1.73e-14 | 9.22e-13 | 102 |
| GO:005164815 | Esophagus | ESCC | vesicle localization | 119/8552 | 177/18723 | 5.16e-09 | 1.08e-07 | 119 |
| GO:00482844 | Esophagus | ESCC | organelle fusion | 94/8552 | 141/18723 | 3.72e-07 | 5.16e-06 | 94 |
| GO:00224069 | Esophagus | ESCC | membrane docking | 62/8552 | 86/18723 | 5.93e-07 | 7.79e-06 | 62 |
| GO:190165319 | Esophagus | ESCC | cellular response to peptide | 208/8552 | 359/18723 | 1.68e-06 | 2.01e-05 | 208 |
| GO:00070308 | Esophagus | ESCC | Golgi organization | 101/8552 | 157/18723 | 1.78e-06 | 2.10e-05 | 101 |
| GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
| GO:003286918 | Esophagus | ESCC | cellular response to insulin stimulus | 124/8552 | 203/18723 | 6.63e-06 | 6.75e-05 | 124 |
| GO:003286818 | Esophagus | ESCC | response to insulin | 156/8552 | 264/18723 | 7.21e-06 | 7.20e-05 | 156 |
| GO:00901743 | Esophagus | ESCC | organelle membrane fusion | 73/8552 | 110/18723 | 9.29e-06 | 8.88e-05 | 73 |
| GO:00069063 | Esophagus | ESCC | vesicle fusion | 70/8552 | 106/18723 | 1.82e-05 | 1.60e-04 | 70 |
| GO:01400567 | Esophagus | ESCC | organelle localization by membrane tethering | 53/8552 | 77/18723 | 3.33e-05 | 2.74e-04 | 53 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| USO1 | SNV | Missense_Mutation | novel | c.1216N>C | p.Glu406Gln | p.E406Q | O60763 | protein_coding | tolerated(0.92) | benign(0.171) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| USO1 | SNV | Missense_Mutation | novel | c.1424N>T | p.Pro475Leu | p.P475L | O60763 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| USO1 | SNV | Missense_Mutation | c.789N>A | p.Met263Ile | p.M263I | O60763 | protein_coding | tolerated(0.18) | benign(0.054) | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| USO1 | SNV | Missense_Mutation | c.2558N>G | p.Lys853Arg | p.K853R | O60763 | protein_coding | tolerated(0.18) | benign(0.003) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| USO1 | SNV | Missense_Mutation | c.2254N>C | p.Glu752Gln | p.E752Q | O60763 | protein_coding | tolerated(0.13) | possibly_damaging(0.572) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| USO1 | SNV | Missense_Mutation | c.2012N>C | p.Arg671Pro | p.R671P | O60763 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| USO1 | SNV | Missense_Mutation | c.893C>T | p.Thr298Ile | p.T298I | O60763 | protein_coding | tolerated(0.09) | benign(0.125) | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| USO1 | SNV | Missense_Mutation | rs781622240 | c.2918T>C | p.Ile973Thr | p.I973T | O60763 | protein_coding | deleterious_low_confidence(0) | benign(0.025) | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| USO1 | SNV | Missense_Mutation | c.2012N>C | p.Arg671Pro | p.R671P | O60763 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| USO1 | insertion | Frame_Shift_Ins | novel | c.2882_2883insAAGAAAC | p.Asp961GlufsTer4 | p.D961Efs*4 | O60763 | protein_coding | TCGA-BH-A0B4-01 | Breast | breast invasive carcinoma | Male | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |